stella
beta
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer — Stella
Recruiting
Back to Non-small Cell Lung Cancer (NSCLC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
View full record on ClinicalTrials.gov